
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is attractive fundamentally because its Phase 2 CALMA trial for IGC-AD1 has already shown clinically and statistically significant agitation reduction versus placebo in March 2024, de-risking the lead program with human proof-of-concept. The company also reported in August that it reached its original 146-patient enrollment target and is now within 6 additional randomizations of closure, while earlier April progress showed over 80% enrollment, indicating strong operational execution and near-term milestone visibility. With a billion-dollar market potential, and multiple catalysts such as completion of CALMA and the AI beta program in mid-2026, the stock offers a compelling risk-reward profile despite the long development path.
Bears say
IGC Pharma is an early-stage, clinical company with minimal revenue generation, and its Q2 2026 results showed just $0.3 million in revenue against a $2.9 million net loss, highlighting a business model that remains heavily dependent on future scientific and regulatory success. Its Alzheimer’s-focused pipeline may address a large unmet need, but the company still faces significant execution risk because its candidates must prove safety and efficacy in clinical trials, gain regulatory approval, and ultimately achieve commercialization and reimbursement. Given the balance sheet and liquidity risks, ongoing losses, and broad biotech sensitivity to investor sentiment and macroeconomic conditions, the fundamentals support a negative outlook.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares